{"entity":{"id":"bond-003","kind":"trial","name":"BOND-003","aka":[],"tldr":"A cancer-killing virus instilled into the bladder produced complete responses in three quarters of patients whose BCG had failed, with almost no serious side effects.","summary":"BOND-003, trial NCT04452591 sponsored by CG Oncology and reported in 2024 with publication in Lancet Oncology in 2025, showed that a cancer-killing virus instilled into the bladder produced complete responses in three quarters of patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer with carcinoma in situ, with almost no serious side effects. In the single-arm cohort C of 110 patients, complete response at any time was 75.2 percent and 41.8 percent at 24 months, with no severe treatment-related events, and a rolling licence application is under way in 2026. OnCo links it to bladder cancer, oncolytic viruses, cretostimogene grenadenorepvec and the BCG-unresponsive term. It is a single-arm registrational study, with the randomised PIVOT-006 and CORE-008 ongoing, so durability against comparators is the open question.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT04452591","url":"https://clinicaltrials.gov/study/NCT04452591"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":["cretostimogene"],"companies":["cg-oncology"],"institutions":[],"pathways":[],"terms":["bcg-unresponsive"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04452591","phase":"3","setting":"BCG-unresponsive high-risk NMIBC with CIS: intravesical cretostimogene grenadenorepvec, single arm (cohort C)","sponsor":"CG Oncology","result":"CR 75.2%; 24-month CR 41.8%.","started":"2020-10-27","startedType":"actual","yearReported":2024,"enrolled":110,"enrolledBasis":"registry","outcomes":[{"endpoint":"Complete response at any time","primary":true,"unit":"%","arms":[{"name":"Cretostimogene","n":110,"value":75.2}],"source":"https://pubmed.ncbi.nlm.nih.gov/42508433/"},{"endpoint":"Complete response at 24 months","unit":"%","arms":[{"name":"Cretostimogene","value":41.8}],"source":"https://doi.org/10.1016/S1470-2045(26)00194-4"}],"replication":"Single-arm registrational; PIVOT-006 (intermediate-risk, randomised) and CORE-008 (BCG-naive) ongoing."},"route":"/trials/bond-003/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"technology":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"}],"drug":[{"id":"cretostimogene","kind":"drug","name":"Cretostimogene grenadenorepvec","route":"/drugs/cretostimogene/"}],"company":[{"id":"cg-oncology","kind":"company","name":"CG Oncology","route":"/companies/cg-oncology/"}],"term":[{"id":"bcg-unresponsive","kind":"term","name":"BCG-unresponsive","route":"/terms/bcg-unresponsive/"}]}}